|
Title
|
|
|
|
Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Introduction: Bipolar disorder is a severe, chronic psychiatric disorder with a need for long-term treatment. Patient nonadherence is frequent and poses a major problem in maintenance therapy. Aripiprazole once-monthly long-acting injectable (AOM LAI) is a recently US Food and Drug Administration-approved treatment option for maintenance therapy that could be of great value. Areas covered: This paper reviews the pharmacokinetic, efficacy and safety data for AOM LAI in bipolar disorder. Expert opinion: AOM LAI is a safe and efficacious treatment option in the maintenance therapy of bipolar I disorder. However, further research is still needed to determine the position of AOM LAI relative to other available treatment options. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
|
|
|
Publication
|
|
|
|
2018
|
|
|
DOI
|
|
|
|
10.1080/17425255.2018.1515911
|
|
|
Volume/pages
|
|
|
|
14
:10
(2018)
, p. 999-1005
|
|
|
ISI
|
|
|
|
000447620100002
|
|
|
Pubmed ID
|
|
|
|
30141352
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (open access)
|
|
|
|
|
|